Read more: Click here to read the original, longer version of this story. AND… breathe. Twenty-six years after the gene implicated in cystic fibrosis was found, gene therapy has been able to help ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe. Cystic ...

VERVE-102 cut LDL cholesterol by about 62% in an early trial, most helpful for those with family history, but more diverse ...

Gene therapy represents one of medicine’s most ambitious attempts to treat disease at its root cause by altering the genetic code itself. The approach works by recovering the functions of critical ...

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment opportunity for sickle cell disease and β-thalassemia. The discovery, ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine This voice experience is generated by AI. Learn more. This ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger ...

"This was the first proof that 'gene therapy in a box' could work." Gene therapies or cell therapies that involve genetically modified cells today are available at only a limited number of research ...

Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that results from mutations in the DMD gene. Gene therapies for DMD change genetic material in a person’s body to treat this condition.

LONDON, May 2, 2023 /PRNewswire/ -- Clarivate Plc (CLVT) (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced the ...

GJB2 gene therapy enters human testing for the first time as Skylark Bio doses the first child in the SONIX Phase 1/2 trial, ...

WASHINGTON – A first attempt at gene therapy for a disease that leaves babies unable to move, swallow and, eventually, breathe has extended the tots’ lives, and some began to roll over, sit and stand ...